A detailed history of Ubs Group Ag transactions in Gh Research PLC stock. As of the latest transaction made, Ubs Group Ag holds 646 shares of GHRS stock, worth $4,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares
646
Holding current value
$4,580
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.69 - $12.49 $4,321 - $8,068
646 New
646 $4,000
Q1 2024

May 13, 2024

BUY
$5.34 - $11.09 $1,116 - $2,317
209 New
209 $2,000
Q2 2022

Aug 10, 2022

SELL
$8.99 - $19.87 $899 - $1,987
-100 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$15.48 - $23.98 $1,548 - $2,398
100 New
100 $2,000
Q3 2021

Nov 15, 2021

SELL
$16.51 - $23.68 $5,530 - $7,932
-335 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$19.25 - $21.73 $6,448 - $7,279
335 New
335 $7,000

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $369M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.